Mylan Launches Generic Version of Clarinex® Allergy Medication

Mylan Inc.

today announced that its subsidiary Mylan Pharmaceuticals Inc. has launched Desloratadine Tablets, 5 mg, the generic version of Schering-Plough's Clarinex® allergy medication. Mylan previously received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Desloratadine Tablets, 5 mg, and is shipping this product immediately. Desloratadine Tablets, 5 mg, had U.S. sales of approximately $194.6 million for the 12 months ending March 31, 2012, according to IMS Health. Currently, Mylan has 167 ANDAs pending FDA approval representing $83.8 billion in annual sales, according to IMS Health. Thirty-seven of these pending ANDAs are potential first-to-file opportunities, representing $25.6 billion in annual brand sales, for the 12 months ending Dec. 31, 2011, according to IMS Health.